熱門資訊> 正文

Corcept寻求FDA批准用于卵巢癌治疗

2025-07-14 22:06

Corcept Therapeutics (NASDAQ:CORT) has submitted a marketing application to the U.S. FDA for its cortisol modulator, Relacorilant, a drug designed to help patients with ovarian cancer that does not respond to platinum-based treatments.
The application is supported by positive results from its recent studies.
Stock is up 1%.

More on Corcept Therapeutics

Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
Corcept's mid-stage ALS study fails to meet main goal
Corcept projects $900M-$950M revenue for 2025 amid advancing hypercortisolism treatments

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。